Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits
- 162 Downloads
Current biopsy planning based on contrast-enhanced T1W (CET1W) or FLAIR sequences frequently delivers biopsy samples that are not in concordance with the gross tumor diagnosis. This study investigates whether the quantitative information of transfer constant Ktrans maps derived from T1W dynamic contrast-enhanced MRI (DCE-MRI) can help enhance the quality of biopsy target selection in glioma. 28 patients with suspected glioma received MRI including DCE-MRI and a standard neuronavigation protocol of 3D FLAIR- and CET1W data sets (0.1 mmol/kg gadobutrol) at 3.0 T. After exclusion of five cases with no Ktrans-elevation, 2–6 biopsy targets were independently selected by a neurosurgeon (samples based on standard imaging) and a neuroradiologist (samples based on kinetic parameter Ktrans) per case and tissue samples corresponding to these targets were collected by a separate independent neurosurgeon. Standard technique and Ktrans-based samples were rated for diagnostic concordance with the gross tumor resection reference diagnosis (67 WHO IV; 24 WHO III and II) by a neuropathologist blinded for selection mode. Ktrans-based sample targets differed from standard technique sample targets in 90/91 cases. More Ktrans-based than standard imaging-based samples could be extracted. Diagnoses from Ktrans-based samples were more frequently concordant with the reference gross tumor diagnoses than those from standard imaging-based samples (WHO IV: 30/39 vs. 11/20; p = 0.08; WHO III/II: 12/13 vs. 6/11; p = 0.06). In 4/5 non-contrast-enhancing gliomas, Ktrans-based selection revealed significantly more accurate samples than standard technique sample-selection (10/12 vs. 2/8 samples; p = 0.02). If Ktrans elevation is present, Ktrans-based biopsy targeting provides significantly more diagnostic tissue samples in non-contrast-enhancing glioma than selection based on CET1W and FLAIR-weighted images alone.
KeywordsBiopsy targeting Selection Glioma Ktrans DCE-MRI Benefit
- CET1W MRI
Contrast-enhanced T1-weighted MRI
T2*-dynamic susceptibility-weighted MRI
T1W dynamic contrast-enhanced MRI
presumed diagnosis based on target tissue sample only
reference diagnosis from the completely resected gross tumor
reflux volume transfer constant (of contrast agent)
efflux volume transfer constant (of contrast agent)
extracellular-extravascular volume fraction (of contrast agent)
World Health Organization
Neither of the authors did receive any funding from the company or any third parties for this study nor did anybody received payments related to this study. The study is investigator-initiated and received no funding from third parties.
Compliance with ethical standards
Conflict of interest
V.C.K. received compensation for an invited talk at a Philips User Meeting in Switzerland in 2015. J.G. is employed by Philips Healthcare, the company providing both MRI and software used in this study.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 3.Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, Geisler J, La Fougere C, Lutz J, Linn J, Kreth S, von Deimling A, Tonn JC, Kretzschmar HA, Popperl G, Kreth FW (2011) Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 13:307–316. doi: 10.1093/neuonc/noq196 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavare S (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110:4009–4014. doi: 10.1073/pnas.1219747110 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Ganslandt O, Stadlbauer A, Fahlbusch R, Kamada K, Buslei R, Blumcke I, Moser E, Nimsky C (2005) Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery 56:291–298 (discussion 291–298)PubMedGoogle Scholar
- 7.Hermann EJ, Hattingen E, Krauss JK, Marquardt G, Pilatus U, Franz K, Setzer M, Gasser T, Tews DS, Zanella FE, Seifert V, Lanfermann H (2008) Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg 86:300–307. doi: 10.1159/000155232 CrossRefPubMedGoogle Scholar
- 8.Weber MA, Henze M, Tuttenberg J, Stieltjes B, Meissner M, Zimmer F, Burkholder I, Kroll A, Combs SE, Vogt-Schaden M, Giesel FL, Zoubaa S, Haberkorn U, Kauczor HU, Essig M (2010) Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? Invest Radiol 45:755–768. doi: 10.1097/RLI.0b013e3181ec9db0 CrossRefPubMedGoogle Scholar
- 9.Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN, Brinkmann DH (2013) Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 15:1058–1067. doi: 10.1093/neuonc/not002 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Lopez WO, Cordeiro JG, Albicker U, Doostkam S, Nikkhah G, Kirch RD, Trippel M, Reithmeier T (2015) Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool. Onco Targets Ther 8:3803–3815. doi: 10.2147/OTT.S87126 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Roessler K, Gatterbauer B, Becherer A, Paul M, Kletter K, Prayer D, Hoeftberger R, Hainfellner J, Asenbaum S, Knosp E (2007) Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg 50:273–280. doi: 10.1055/s-2007-991143 CrossRefPubMedGoogle Scholar
- 17.Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMedGoogle Scholar
- 21.Dujardin MI, Sourbron SP, Chaskis C, Verellen D, Stadnik T, de Mey J, Luypaert R (2012) Quantification of cerebral tumour blood flow and permeability with T1-weighted dynamic contrast enhanced MRI: a feasibility study. J Neuroradiol 39:227–235. doi: 10.1016/j.neurad.2011.07.001 CrossRefPubMedGoogle Scholar
- 22.Jia ZZ, Geng DY, Liu Y, Chen XR, Zhang J (2013) Microvascular permeability of brain astrocytoma with contrast-enhanced magnetic resonance imaging: correlation analysis with histopathologic grade. Chin Med J (Engl) 126:1953–1956Google Scholar
- 24.An YS, Kang DK, Jung YS, Han S, Kim TH (2015) Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: correlation with tumor subtype and histologic prognostic factors. Eur J Radiol 84:1365–1370. doi: 10.1016/j.ejrad.2015.03.026 CrossRefPubMedGoogle Scholar
- 25.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. doi: 10.1007/s00401-016-1545-1 CrossRefPubMedGoogle Scholar
- 28.Della Puppa A, Persano L, Masi G, Rampazzo E, Sinigaglia A, Pistollato F, Denaro L, Barzon L, Palu G, Basso G, Scienza R, d’Avella D (2012) MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients? J Neurooncol 106:33–41. doi: 10.1007/s11060-011-0639-9 CrossRefPubMedGoogle Scholar
- 30.Pedeutour-Braccini Z, Burel-Vandenbos F, Goze C, Roger C, Bazin A, Costes-Martineau V, Duffau H, Rigau V (2015) Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification? Virchows Arch 466:433–444. doi: 10.1007/s00428-014-1712-5 CrossRefPubMedGoogle Scholar
- 31.Widhalm G, Kiesel B, Woehrer A, Traub-Weidinger T, Preusser M, Marosi C, Prayer D, Hainfellner JA, Knosp E, Wolfsberger S (2013) 5-Aminolevulinic acid induced fluorescence is a powerful intraoperative marker for precise histopathological grading of gliomas with non-significant contrast-enhancement. PLoS ONE 8:e76988. doi: 10.1371/journal.pone.0076988 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Cordova JS, Shu HK, Liang Z, Gurbani SS, Cooper LA, Holder CA, Olson JJ, Kairdolf B, Schreibmann E, Neill SG, Hadjipanayis CG, Shim H (2016) Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients. Neuro Oncol 18:1180–1189. doi: 10.1093/neuonc/now036 CrossRefPubMedGoogle Scholar
- 42.van Niekerk CG, van der Laak JA, Hambrock T, Huisman HJ, Witjes JA, Barentsz JO, Hulsbergen-van de Kaa CA (2014) Correlation between dynamic contrast-enhanced MRI and quantitative histopathologic microvascular parameters in organ-confined prostate cancer. Eur Radiol 24:2597–2605. doi: 10.1007/s00330-014-3301-z CrossRefPubMedGoogle Scholar
- 45.Lavini C, Verhoeff JJ, Majoie CB, Stalpers LJ, Richel DJ, Maas M (2011) Model-based, semiquantitative and time intensity curve shape analysis of dynamic contrast-enhanced MRI: a comparison in patients undergoing antiangiogenic treatment for recurrent glioma. J Magn Reson Imaging 34:1303–1312. doi: 10.1002/jmri.22742 CrossRefPubMedGoogle Scholar
- 46.Weber MA, Zoubaa S, Schlieter M, Juttler E, Huttner HB, Geletneky K, Ittrich C, Lichy MP, Kroll A, Debus J, Giesel FL, Hartmann M, Essig M (2006) Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology 66:1899–1906. doi: 10.1212/01.wnl.0000219767.49705.9c CrossRefPubMedGoogle Scholar